奥沙利铂与方克联合方案治疗进展期结直肠癌的随机对照研究  

Tegafur combined with oxaliplatin for advanced colorectal cancer:a randomized controlled study

作　　者：刘凌翔[1] 刘平[1] 黄普文[1] 殷咏梅[1] 王榕生[1] 穆庆霞[1] 卢凯华[1] 束永前[1] 

机构地区：[1]南京医科大学第一附属医院,江苏南京210029

出　　处：《临床和实验医学杂志》2006年第1期14-16,共3页Journal of Clinical and Experimental Medicine

摘　　要：目的比较奥沙利铂(L-OHP)、亚叶酸钙(LV)联合替加氟注射液与FOLFOX4方案(L-OHP、LV联合静脉维持氟脲嘧啶)治疗进展期结直肠癌的疗效和毒副作用。方法将病理检查确诊的60例进展期结直肠癌患者随机分成两组,L-OHP、LV联合替加氟注射液组(A组)30例,L-OHP、LV联合5-FU组(B组)30例。结果A组总有效率为39.3%,中位生存期11.6个月,中位无进展生存期9.5个月。B组有效率为48.1%,中位生存期12.1个月,中位无进展生存期9.4个月。两组间无显著差异(P>0.05)。A组治疗期间的PS评分高于B组(P<0.001)。两组毒副作用未见明显差异。结论奥沙利铂、亚叶酸钙联合替加氟注射液与FOLFOX4方案治疗进展期结直肠癌,疗效和毒性相似。应用前者,患者生活质量较高,值得进一步研究。Objective To determine the activity and side - effect of tegarfur injection combined with L - OttP and 5 - FU, comparing with FOLFOX4 as the therapy for advanced coloreetal cancer . Methods 60 patient s, proved pathologic＇ally, were divided into 2 groups at raudom. Group A reeeived the intravenous adminis tration of tegafur, leueovorin and L-OHP. FOLFOX4 was applied in the group B. Results The response rule was 39.3% in the group A, while median time to progression was 9.5 months with rnedian surival time of 11.6 months. In the group B, the response nale was,48. 1% and median time to progression was 9 .d. months with median survival time of 12.1 months. No sigifieant differences were found between treatme nt ams, in curative effect, survival time and side effeet. （ P 〉 0.05）, With respect to QOL, the group A acguwxl higher PS titan B during treatment. （ P 〈 0. 001 ）. Conclusion The intravenous athninistration of tega/ur, leucovorin anti L- OHP is a wall -tolented, effective, and feasible schedule for advanced eolorcctal cancer that yields comparable efficacy anti side effect compared with FOLFOX4, Meanwhile, the former improves their QOL when treated with chemotherapy. prospective trials are warranted to be worth.

关 键 词：结直肠癌 奥沙利铂 替加氟注射液 

分 类 号：R735.3[医药卫生—肿瘤]